首页> 外国专利> Preparation of optically pure (3RS)-2-oxy-3-(2-thienyl)-propylamine compound, useful as drug intermediate for e.g. serotonin and norepinephrine uptake inhibitor duloxetine, by enantioselective Reformatsky type synthesis via new intermediate

Preparation of optically pure (3RS)-2-oxy-3-(2-thienyl)-propylamine compound, useful as drug intermediate for e.g. serotonin and norepinephrine uptake inhibitor duloxetine, by enantioselective Reformatsky type synthesis via new intermediate

机译:制备光学纯的(3RS)-2-氧基-3-(2-噻吩基)-丙胺化合物,用作例如药物中间体。 5-羟色胺和去甲肾上腺素摄取抑制剂度洛西汀,通过新中间体对映选择性Reformatsky型合成

摘要

Preparation of (3R)- or (3S)-2-oxy-3-(2-thienyl)-propylamines (I) involves: (i) reacting a 2-thiophene-carboxaldehyde (II) with a reactive halo compound (III) and zinc in presence of an enantiomerically pure chiral auxiliary having at least two amino groups; (ii) adding water, acid or base or an alkylating, arylating, esterifying or silylating reagent; (iii) adding an amine (IV); and (iv) reducing product. Preparation of (3R)- or (3S)-2-oxy-3-(2-thienyl)-propylamines of formula (I) involves: (i) reacting a 2-thiophene-carboxaldehyde of formula (II) with a reactive halo compound of formula Hal-CR3R4-Y (III) and zinc in presence of an enantiomerically pure chiral auxiliary having at least two amino groups (provided that the protons present have a pKa of more than 20; (ii) adding water, acid or base or an alkylating, arylating, esterifying or silylating reagent; (iii) if Y is COOR1 or COOSi(Rs)3 adding an amine of formula NHR1R2 (IV); and (iv) reducing the product. R1, R2 = H or 1-30C hydrocarbyl ; R3 - R7 = halo or as defined for R1; Rx = H or 1-30C hydrocarbyl; W = H, alkyl, aryl, acyl or silyl; Y = CN or COZ; Z = OR1, OSi(Rs)3 or NR1R2; Rs = 1-30C hydrocarbyl; Hal = Cl, Br or I. The OW group in (I) is in alpha- or beta-configuration. 1-30C Hydrocarbyl either: (a) is optionally substituted by halo or CN; or (b) has one or more non-adjacent CH2 units replaced by O, CO, COO, OCO, OCOO, S or NRx; and/or (c) has one or more CH units replaced by N or P. Independent claims are included for the following new intermediates: (1) (3R)- or (3S)-2-oxy-3-(2-thienyl)-propionic acid amides, esters, silyl esters or nitriles of formula (V) (including mixtures of the (3R)- and (3S)-isomers in the case of amides) and (2) enantiomerically pure (3S)-3-hydroxy-3-(2-thienyl)-propionate esters of formula (VII). Q = CONR1R2, COOR1, COOSi(Rs)3 or CN; Ra = optionally halo- or cyano-substituted 2-30C hydrocarbyl; W' = H, alkyl, aryl, acyl, silyl or CORa. The OW group in (V) is in either the alpha- or beta-configuration, or may also be a mixture if Q = CONR1R2. When W is alkyl, aryl, silyl or CORa then Q is COOR1; and when R5 - R7 is H then Q is CN.
机译:(3R)-或(3S)-2-氧基-3-(2-噻吩基)-丙胺的制备(I)涉及:(i)使2-噻吩甲醛(II)与反应性卤代化合物(III)反应在具有至少两个氨基的对映体纯的手性助剂存在下的锌;和(ii)加入水,酸或碱或烷基化,芳基化,酯化或甲硅烷基化试剂; (iii)添加胺(IV); (iv)减少产品。式(I)的(3R)-或(3S)-2-氧基-3-(2-噻吩基)-丙胺的制备涉及:(i)使式(II)的2-噻吩-甲醛与反应性卤素反应在具有至少两个氨基的对映体纯的手性助剂的存在下,式Hal-CR3R4-Y(III)的化合物和锌(条件是存在的质子的pKa大于20;(ii)添加水,酸或碱(iii)如果Y为COOR1或COOSi(Rs)3,则添加式NHR1R2(IV)的胺;和(iv)还原产物R1,R2 = H或1- 30C烃基; R3-R7 =卤素或R1定义; Rx = H或1-30C烃基; W = H,烷基,芳基,酰基或甲硅烷基; Y = CN或COZ; Z = OR1,OSi(Rs)3 (I)中的OW基为α-或β-构型。1-30C烃基为:(a)任选被卤素或CN取代;或NR1R2; Rs = 1-30C烃基; Hal = Cl,Br或I. ;或(b)更换了一个或多个不相邻的CH2单元b y O,CO,COO,OCO,OCOO,S或NRx;和/或(c)的一个或多个CH单元被N或P取代。下列新中间体包括独立权利要求:(1)(3R)-或(3S)-2-氧基-3-(2-噻吩基) )-式(V)的丙酸酰胺,酯,甲硅烷基酯或腈(在酰胺的情况下包括(3R)-和(3S)-异构体的混合物)和(2)对映体纯的(3S)-3-式(VII)的羟基-3-(2-噻吩基)-丙酸酯。 Q = CONR1R2,COOR1,COOSi(Rs)3或CN; Ra =任选地被卤素或氰基取代的2-30C烃基; W'= H,烷基,芳基,酰基,甲硅烷基或CORa。 (V)中的OW基为α或β构型,如果Q = CONR1R2,也可以为混合物。当W为烷基,芳基,甲硅烷基或CORa时,则Q为COOR1;当R5-R7为H时,Q为CN。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号